الصفحة الرئيسية>>Signaling Pathways>> Metabolism>> Phospholipase>>ML 349

ML 349

رقم الكتالوجGC17889

ML 349 هو مثبط قوي ومحدد لبروتين الأسيل ثيويستيراز 2 (APT2) / ليسوفوسفوليباز 2 (LYPLA2) مع Ki يبلغ 120 نانومتر. ML 349 هو أيضًا مثبط لـ LYPLA2 مع IC50 من 144 نانومتر.

Products are for research use only. Not for human use. We do not sell to patients.

ML 349 التركيب الكيميائي

Cas No.: 890819-86-0

الحجم السعر المخزون الكميّة
1mg
35٫00
متوفر
5mg
105٫00
متوفر
10mg
194٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

ML349 is a potent and specific acyl protein thioesterase 2 (APT-2) inhibitor with a Ki of 120 nM. ML349 is also an inhibitor of LYPLA2 with an IC50 of 144 nM.

ML349 is an inhibitor of acyl protein thioesterase 1 and 2 (APT-1 and APT-2) with Kis of >10000 and 120±20 nM, respectively[1]. ML349 is also an inhibitor of both LYPLA1 and LYPLA2 with IC50s of >3000 and 144 nM, respectivley[2]. ML348 and ML349 do not decrease cell viability, but they lead to a slight activation of AKT in NRAS mutant cells[3].

References:
[1]. Won SJ, et al. Molecular Mechanism for Isoform-Selective Inhibition of Acyl Protein Thioesterases 1 and 2 (APT1 and APT2). ACS Chem Biol. 2016 Dec 16;11(12):3374-3382.
[2]. Adibekian A, et al. Characterization of a Selective, Reversible Inhibitor of Lysophospholipase 2 (LYPLA2).
[3]. Vujic I, et al. Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells. Oncotarget. 2016 Feb 9;7(6):7297-306.

مراجعات

Review for ML 349

Average Rating: 5 ★★★★★ (Based on Reviews and 12 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ML 349

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.